Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients

Cancer

Volumn 107, Issue 11, 2006, Pages 2604-2608

  Hupertan, Vincent ^a,b   Roupret, Morgan ^a,c   Poisson, Jean Francois ^a   Chretien, Yves ^a   Dufour, Bertrand ^a   Thiounn, Nicolas ^a   Mejean, Arnaud ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ LUMIÈRE LYON 2   (France)

^c NONE   (France)

Author keywords

Carcinoma; Neoplasms; Prognosis; Proportional hazards models; Renal cell; Statistical model

Indexed keywords

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FRANCE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NEPHRECTOMY; NOMOGRAM; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

CARCINOMA, RENAL CELL; FEMALE; FRANCE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS;

EID: 33751584449     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22313     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Patard JJ, Tazi H, Bensalah K, et al. The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol. 2004;45:490-494.
3. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int. 2006;97:939-945.
4. Mejean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol. 2003;169:821-827.
5. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
6. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.
7. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58:141-145.
8. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20:1368-1374.
9. Hixson ED, Kattan MW. Nomograms are more meaningful than severity-adjusted institutional comparisons for reporting outcomes. Eur Urol. 2006;49:600-603.
10. Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, Tl or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173:1518-1525.
11. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-7012.
12. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104:1362-1371.
13. Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol. 2003;170:S6-10.
14. Sobin LH, Wittekind CH.Urological tumors. In: TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, 1997:165-194.
15. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
16. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123.
17. Steyerberg EW, Harrell FE Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y. Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774-781.
18. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515-524.
19. Rowland JJ. Model selection methodology in supervised learning with evolutionary computation. Biosystems. 2003;72:187-196.
20. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48-51.
21. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn. 2005;32:185-197.
22. Hainsworth JD, Sosman JA. Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23:7889-7896.
23. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.